Urologists and uro-oncologists are familiar with this concept from the D’Amico risk index based on the pre-treatment prostate-specific antigen (PSA) level, Gleason score, and tumor stage [39] concerning biochemical outcomes for localized PCa. This evidence concerns the gene KLK3 and posterior cortical atrophy.